Strides Pharma Science Ltd.

NSE: STAR BSE: 532531 SECTOR: Pharmaceuticals & Drugs  31k   91   24

356.40
+8.80 (2.53%)
NSE: Today, 04:13 PM

Price Summary

Today's High

₹ 365

Today's Low

₹ 347.85

52 Week High

₹ 643

52 Week Low

₹ 263.35

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3200.6 Cr.

Enterprise Value

4006.5 Cr.

No. of Shares

8.98 Cr.

P/E

23.68

P/B

0.96

Face Value

₹ 10

Div. Yield

0.7 %

Book Value (TTM)

₹  371.97

CASH

73.04 Cr.

DEBT

878.94 Cr.

Promoter Holding

30.37 %

EPS (TTM)

₹  15.05

Sales Growth

9.79%

ROE

2.45 %

ROCE

4.35%

Profit Growth

-34.95 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.79%
3 Year-1.7%
5 Year-3.52%

Profit Growth

1 Year-34.95%
3 Year-55.56%
5 Year-9.68%

ROE%

1 Year2.45%
3 Year3.22%
5 Year8.2%

ROCE %

1 Year4.35%
3 Year4.51%
5 Year8.16%

Debt/Equity

0.271

Price to Cash Flow

11.32

Interest Cover Ratio

2.70855078896218

CFO/PAT (5 Yr. Avg.)

0.716338301464466

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2022 30.37 62.2
Mar 2022 30.6 56.67
Dec 2021 29.6 37.84
Sep 2021 29.6 26.02
Jun 2021 29.62 26.02
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 28.2478838913131 days.

 Limitations

  • The company has shown a poor profit growth of -55.5620118698625% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.69643874251025% for the Past 3 years.
  • Company has a poor ROE of 3.21714010978269% over the past 3 years.
  • Promoter pledging has increased from 30.6% to 62.2% in 1 quarter.
  • Company has a poor ROCE of 4.50972316690843% over the past 3 years
  • Company has contingent liabilities of 1789.587 Cr.
  • The company is trading at a high PE of 23.68.
  • The company is trading at a high EV/EBITDA of 30.9046.
  • Promoter pledging is high as 62.2%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022
Net Sales 508.79 575 439.56 455.66 423.19
Total Expenditure 503.54 528.03 437.64 437.82 484.22
Operating Profit 5.25 46.96 1.92 17.83 -61.03
Other Income 11.69 22.41 9.22 84.83 7.47
Interest 18.09 18 16.6 21.55 26.02
Depreciation 26.64 27.09 26.23 24.41 24.3
Exceptional Items 0 0 0 0 0
Profit Before Tax -27.79 24.28 -31.69 56.71 -103.88
Tax -6.56 5.76 -14.09 -143.8 -37.63
Profit After Tax -21.23 18.52 -17.6 200.5 -66.25
Adjusted EPS (Rs) -2.37 2.06 -1.96 22.33 -7.38

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 1381.82 1955.4 1537.44 1691.93 1857.57
Total Expenditure 1269.85 1815.21 1403.1 1487.48 1698.34
Operating Profit 111.97 140.2 134.34 204.46 159.23
Other Income 169.06 1001.72 114.61 93.07 117.09
Interest 71.96 81.97 54.09 66.84 65.34
Depreciation 70.01 114.77 83 94.24 99.34
Exceptional Items -15.16 -29.38 -3.52 0 0
Profit Before Tax 123.9 915.8 108.33 136.45 111.64
Tax 15.36 24.21 -2.04 16.17 33.4
Net Profit 108.54 891.59 110.37 120.28 78.24
Adjusted EPS (Rs.) 12.14 99.62 12.32 13.43 8.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 89.42 89.5 89.55 89.57 89.68
Total Reserves 3143.1 3072.52 3167.25 3069.22 3158.38
Borrowings 769.45 2.45 0.15 0 147.54
Other N/C liabilities 25.77 -36.86 -63.27 -37.31 159.89
Current liabilities 1434.16 1104.05 1388.99 1454.95 1590.64
Total Liabilities 5461.9 4231.65 4582.68 4576.42 5146.12
Assets
Net Block 1123.76 497.96 496.73 578.35 576.66
Capital WIP 99.63 86.89 72.56 89.47 81.36
Intangible WIP 58.12 56.97 49.9 22.78 29.31
Investments 1310.77 1531.19 2071.47 2242.91 2462.48
Loans & Advances 204.05 154.76 223.27 237.29 247.33
Other N/C Assets 86.41 404.35 5.16 10.1 5.13
Current Assets 2579.16 1499.54 1663.59 1395.53 1743.86
Total Assets 5461.9 4231.65 4582.68 4576.42 5146.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 123.9 915.8 108.33 136.45 111.64
Adjustment 193.49 -670.77 90.19 130.28 114.15
Changes in Assets & Liabilities 131.16 -161.75 -121.04 -96.91 -109.81
Tax Paid -36.81 -17.68 -37.52 -32.18 166.79
Operating Cash Flow 411.74 65.59 39.97 137.64 282.76
Investing Cash Flow -882.82 432.96 -166.06 62.83 -275.64
Financing Cash Flow -67.24 -706.77 123.26 -203.56 -48.64
Net Cash Flow -538.32 -208.22 -2.83 -3.09 -41.52

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Promoters 29.62 29.60 29.60 30.60 30.37
pronomz ventures l... 14.14 14.14 14.14 14.14 14.14
sequent scientific... 3.70 3.70 3.70 3.70 3.70
abusha investment ... 0.31 0.31 0.31 0.31 0.31
arun kumar pillai 1.53 1.53 1.53 1.53 1.53
lifecell internati... 1.56 - 1.56 1.56 1.56
k r ravishankar 1.40 1.40 1.40 1.40 1.40
karuna business so... 0.67 0.67 0.67 0.67 0.67
devendra estates l... 1.23 0.92 0.92 0.92 0.92
shasun leasing and... 1.08 1.12 1.12 1.12 1.12
rupali jatin 0.22 0.21 0.21 0.21 0.21
vimal kumar s 0.30 0.29 0.29 0.29 0.29
monisha nitin 0.18 0.16 0.16 0.16 0.16
leela v 0.47 0.47 0.47 0.47 0.47
nitin kumar v 0.48 0.56 0.56 0.56 0.56
ambemata securities 0.54 0.54 0.54 0.54 0.54
jatin v 0.44 0.51 0.51 0.51 0.51
chaitanya d 0.37 0.47 0.47 0.47 0.47
chayadeep properti... 0.46 0.46 0.46 0.46 0.46
jitesh d 0.41 0.41 0.41 0.41 0.41
sajjan d 0.18 0.19 0.18 0.19 0.19
aditya arun kumar - - - - -
tarini arun kumar - - - - -
deepa arun kumar - - - - -
padmakumar karunak... 0.19 0.19 0.19 0.19 0.19
vineetha mohanakum... 0.20 0.20 0.20 0.20 0.20
devendra kumar s 0.01 0.01 0.01 0.01 0.01
k r lakshmi 0.15 0.15 0.15 0.15 0.15
vimal kumar s - (... 0.13 0.13 0.13 0.13 0.13
agnus holdings pvt... 0.13 0.13 0.13 0.13 0.13
vimal kumar s - h... - - - - -
sajitha pillai 0.09 0.09 0.09 0.09 0.09
suchi chaitanya sr... 0.10 0.10 0.10 0.10 0.10
pooja srisrimal 0.10 0.10 0.10 0.10 0.10
rajeswari amma 0.10 0.10 0.10 0.10 0.10
s abhaya kumar huf - 0.07 0.07 0.07 0.07
rajitha gopalakris... 0.05 0.05 0.05 0.05 0.05
hemalatha pillai 0.05 0.05 0.05 0.05 0.05
lakshmi gopalakris... 0.06 0.06 0.06 0.06 0.06
gayatri nair 0.04 0.04 0.04 0.04 0.04
purushothaman pill... 0.04 0.04 0.04 0.04 0.04
triumph venture ho... 0.04 0.04 0.04 0.04 0.04
agnus capital llp 0.02 0.02 0.02 0.02 0.02
karuna ventures pr... 0.02 0.02 0.02 0.02 0.02
vibha srisrimal - 0.02 0.02 0.02 0.02
taru mardia - 0.02 0.02 0.02 0.02
rahul nair 0.02 0.02 0.02 0.02 0.02
PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Investors 70.38 70.40 70.40 69.40 69.63
sbi arbitrage oppo... - - - - -
sbi large & midcap... 8.84 - - - -
sbi magnum taxgain... - - 7.89 6.98 -
sbi long term equi... - 7.31 - - 7.60
aditya birla sun l... - - 5.05 - -
aditya birla sun l... - 6.96 - - 6.20
aditya birla sun l... 6.66 - - 5.50 -
life insurance cor... 3.63 3.63 3.63 3.63 3.63
route one offshore... - 4.47 - - -
route one offshore... 4.13 - 4.22 4.33 4.47
bnp paribas arbitr... 3.75 2.70 3.05 3.22 3.27
government pension... 3.16 3.45 3.45 3.45 3.45
route one fund i, ... 2.93 3.00 2.83 2.90 3.00
dsp equity & bond ... 2.91 - 2.91 2.55 -
dsp blackrock equi... - - - - -
brookdale mauritiu... 1.27 1.55 1.81 2.26 2.04
hdfc trustee compa... - - - - -
uti - core equity ... - - - - -
kotak small cap fu... - - - - -
satpal khattar 1.74 1.74 1.74 1.74 1.74
apax global alpha ... 1.47 - 1.47 1.47 -
kotak equity savin... - - - - -
hdfc trustee compa... 1.25 1.25 1.25 1.25 1.25
morgan stanley asi... - - - - 1.19
msd india fund,ltd - - - - -
suresh kumar agarw... - - 1.01 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Strides Pharma Science informs about disclosure10 Aug 2022, 4:52PM Strides Pharma Science informs about disclosure9 Aug 2022, 4:03PM USFDA completes inspection at Strides Pharma Science's Singapore facility9 Aug 2022, 12:40PM Strides Pharma Science informs about press release3 Aug 2022, 4:44PM Strides Pharma's arm gets USFDA’s approval for Cyclosporine Softgel Capsules3 Aug 2022, 2:30PM Strides Pharma Scien - Quaterly Results29 Jul 2022, 1:11PM Strides Pharma Scien - Quaterly Results29 Jul 2022, 1:11PM Strides Pharma Scien - Quaterly Results29 Jul 2022, 1:11PM Strides Pharma Science gets nod to raise Rs 150 crore via NCDs26 Jul 2022, 9:09AM Strides Pharma Science to raise funds through NCDs21 Jul 2022, 11:52AM Strides Pharma Science informs about disclosure8 Jul 2022, 9:52AM Strides Pharma Science informs about press release24 Jun 2022, 11:58AM Strides Pharma Science’s arm gets EU-GMP compliance certificate for two manufacturing facilities16 Jun 2022, 10:57AM Strides Pharma Science informs about press release16 Jun 2022, 9:41AM Strides Pharma Science’s arm recalls over six lakh bottles of Losartan Potassium tablets in US13 Jun 2022, 9:24AM Strides Pharma Science informs about press release10 Jun 2022, 4:55PM Strides Pharma Science’s arm gets USFDA’s nod for Ibuprofen Oral Suspension10 Jun 2022, 4:24PM Strides Pharma Science informs about transcript of the earnings call1 Jun 2022, 12:50PM Strides Pharma Science informs about secretarial compliance report 30 May 2022, 9:42AM Strides Pharma Science informs about press release30 May 2022, 9:40AM Strides Pharma Science’s arm gets USFDA’s nod for Ibuprofen Oral Suspension30 May 2022, 9:19AM Strides Pharma Scien - Quaterly Results24 May 2022, 9:31PM Strides Pharma Scien - Quaterly Results24 May 2022, 9:31PM Strides Pharma Science informs about disclosure28 Apr 2022, 12:47PM Strides Pharma Science informs about disclosure24 Mar 2022, 10:03AM Strides Pharma Science inks sub-license agreement with MPP21 Mar 2022, 9:40AM Strides Pharma Science informs about press release21 Mar 2022, 9:39AM Strides Pharma Science submits newspaper advertisements15 Mar 2022, 1:21PM Strides Pharma Science informs about press release11 Mar 2022, 11:11AM Strides Pharma Science’s arm gets USFDA approval for Colchicine Tablets11 Mar 2022, 10:47AM Strides Pharma Science informs about disclosure5 Mar 2022, 11:28AM Strides Pharma Science informs about disclosure4 Mar 2022, 4:21PM Strides Pharma Science informs about disclosure 4 Mar 2022, 9:13AM Strides Pharma Science informs about disclosure22 Feb 2022, 1:48PM Strides Pharma Science’s arm gets USFDA nod for amantadine hydrochloride softgel capsules 21 Feb 2022, 9:10AM Strides Pharma Scien - Quaterly Results10 Feb 2022, 1:24PM Strides Pharma Scien - Quaterly Results10 Feb 2022, 1:24PM Strides Pharma Scien - Quaterly Results10 Feb 2022, 1:24PM Strides Pharma Science informs about allotment under ESOP28 Jan 2022, 3:38PM Strides Pharma Science, Universal Corporation ink pact with Medicines Patent Pool20 Jan 2022, 3:59PM Strides Pharma Science’s arm gets USFDA approval for Oseltamivir Phosphate for oral suspension18 Jan 2022, 9:15AM Strides Pharma gets DCGI nod under EUA to commercialize Molnupiravir28 Dec 2021, 4:57PM Strides Pharma Science informs about disclosure23 Dec 2021, 10:59AM Strides Pharma Science informs about updates21 Dec 2021, 12:05PM Strides Pharma Science’s Stelis commissions greenfield vaccine manufacturing facility at Bengaluru21 Dec 2021, 9:15AM Strides Pharma Science informs about newspaper advertisement16 Dec 2021, 5:13PM Strides Pharma Science informs about disclosure3 Nov 2021, 12:45PM Strides Pharma Science informs about update21 Oct 2021, 9:42AM Strides Pharma Science informs about disclosure13 Aug 2021, 3:37PM Strides Pharma Science reports consolidated net loss of Rs 205 crore in Q17 Aug 2021, 11:15AM

Strides Pharma Scien Stock Price Analysis and Quick Research Report. Is Strides Pharma Scien an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Strides Pharma Scien and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 282.762 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Strides Pharma Scien has a Debt to Equity ratio of 0.271 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Strides Pharma Scien , the EPS growth was -35.0329143333731 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Strides Pharma Scien has OPM of 8.57202382041878 % which is a bad sign for profitability.
     
  • ROE: Strides Pharma Scien have a poor ROE of 2.44637608654868 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Strides Pharma Scien

X